/
GOVX
$0.72-$0.01 (-1.07%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$3.8M
5M shares
52-week range
$0.64 – $20.00
0% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-1521.78
GeoVax Labs, Inc. New
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
www.geovax.com- Employees
- 19
- IPO / List date
- Feb 1, 1995
- HQ
- SMYRNA, GA
Held by traders on TradeandTell
No one on the platform currently holds GOVX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in GOVX as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-01-12 | 1-for-25reverse |
| 2024-01-31 | 1-for-15reverse |
| 2020-09-25 | 1-for-20reverse |
| 2020-01-24 | 1-for-2000reverse |
| 2019-05-02 | 1-for-500reverse |
Recent trades on TradeandTell
No one on the platform has traded GOVX yet.
